Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | hexokinase | 0.0607 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0607 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0607 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0607 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0607 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.0607 | 1 | 0.5 |
Onchocerca volvulus | 0.0607 | 1 | 1 | |
Echinococcus multilocularis | hexokinase | 0.0607 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0607 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0414 | 0.1468 | 0.1468 |
Onchocerca volvulus | 0.0607 | 1 | 1 | |
Brugia malayi | Hexokinase family protein | 0.0607 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0607 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0607 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.0607 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0607 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0607 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0607 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0607 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0607 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0607 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0607 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0607 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0607 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0607 | 1 | 0.5 |
Onchocerca volvulus | 0.0607 | 1 | 1 | |
Entamoeba histolytica | hexokinase 1 | 0.0607 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0607 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0607 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0607 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.